Pfizer is considering marketing torcetrapib on its own. This is the new HDL-raising drug in the pipeline. In a move to protect their profits, it was originally only paired with Lipitor. Has Pfizer come to its senses? We’ll see:
“The current trial designs might not optimally meet the scientific needs of prescribers, the clinical needs of patients, the economic needs of payers, or the regulatory needs of policymakers,” wrote Professor Avorn.
“But they superbly meet the business needs of the sponsor—to create knowledge in a way that will protect the market share of the largest drug company’s most important drug.”
